Introduction
The study of tumorigenesis provides an opportunity to investigate developmental potential as tumor cells, at least at early stages, recapitulate cellular programs appropriate for the organ of origin. For example, the intestinal epithelium is composed of repeating units, each comprising a crypt of Lieberkü n and either a villus in case of the small intestine or a flat epithelial intestinal compartment in the large intestine; and cancer initiates as stem and progenitor cells overproliferate, do not differentiate and form adenomas that maintain a bcatenin/Tcf-dependent crypt stem cell nature (Humphries and Wright, 2008; Barker et al., 2009) .
In mice, Hh-Gli signaling is essential for normal intestinal development (Ramalho-Santos et al., 2000; Madison et al., 2005; van den Brink et al., 2004) . Secreted Hh glycoproteins trigger a response in cells expressing Patched1 (Ptc1) and Smo, leading to the upregulation of Gli1 and other targets, including Ptc1 itself. Both early intestinal stem cells and the mature mesenchyme that surrounds the intestinal epithelium respond to Hh-Gli signaling. For instance, myofibroblasts of the surrounding mesenchyme express high levels of Ptc1, and there are also Ptc1 + cells in the serosa and villus smooth muscle (Madison et al., 2005; Kolterud et al., 2009) . For source of Hh ligands, it has been proposed that Shh is produced by crypt cells (van den Brink et al., 2002 ; but see van den Brink and Peppelenbosch, 2006; van Dop et al., 2009) , whereas Indian Hh appears to be produced by villi and crypts in the small intestine where it promotes differentiation antagonizing the pro-proliferative action of Wnt signaling from the crypt base (van den Brink et al., 2004; Varnat et al., 2006) . The exact location of cells acting as sources of Shh at the crypt bottom, however, is not clear. Inhibition of Hh signaling in the intestinal epithelium through the expression of the antagonist Hip leads to abnormal villus development, an increase in cell proliferation and the enhancement of Tcf targets (Madison et al., 2005) . This suggests that the responding cells expressing the Hh receptor Ptc1 and Smo, the latter of which is essential to transduce the signal intracellularly, act in a paracrine loop to repress proliferation of crypt cells, thus insuring the normal development of a crypt-villus axis in coordination with the mesenchymal compartment. The signal sent back from the mesenchyme to the epithelium remains unclear. Taken together, these results have been interpreted to suggest that Hh signaling acts to repress intestinal proliferation, possibly enhancing cell differentiation (van den Brink et al., 2004; Madison et al., 2005; Kolterud et al., 2009) . Consistent with this idea, enhancement of Hh signaling through inactivation of Ptc1 in adult mice leads to myofibroblast accumulation, crypt reduction and inhibition of Wnt signaling (van Dop et al., 2009) .
The studies summarized above suggest that human colon cancers, which recapitulate crypt cell identity at early stages (van den Brink et al. 2002; van de Wetering et al., 2002) , should be insensitive to HH inhibition, or worse, inhibition could lead to enhanced cancer cell proliferation. While we have recently demonstrated that this is not the case and that HH-GLI pathway inhibition in human colon cancers represents a valid therapeutic avenue (Varnat et al., 2009) , it remained unclear if inhibition of Hh-Gli activity in mice could be beneficial and inhibit tumor development in the intestine, thus providing a model for human disease. We thus sought to test the role of Hh signaling in mouse intestinal tumors directly by deleting Smo in mice lacking Apc, the latter of which produces the formation of intestinal adenomas through hyperactivation of bcatenin/Tcf function (Su et al., 1992; Shibata et al., 1997) .
While this paper was being prepared, a study has shown that germ-line heterozygote mice lacking one copy of Smo have a small but noticeable decrease in the number of adenomas formed by reduced Apc function (Arimura et al., 2009 (Park et al., 2000) and Shh Cre-GFP (Harfe et al., 2004) knock-in lines in which b-Gal or GFP are expressed in Gli1 + or Shh + cells, respectively. Histological analyses followed by X-Gal staining showed that b-galactosidase (b-Gal) activity was found in mesenchymal cells surrounding the crypts with rare cells being partially inside ( Fig. 1A ; see also Kolterud et al., 2009) . Using a Shh
Cre-GFP ;Rosa26 line in which Cre expressed from Shh + cells drives recombination in the Rosa locus and the activation of the LacZ reporter, we found, in contrast, that the entire intestinal epithelium was b-Gal + (Fig. 1B) , and thus derived from cells expressing or that had expressed Shh. The surrounding mesenchyme was negative (Fig. 1B) ). Apc mutant mice develop intestinal tumors (Shibata et al., 1997; Su et al., 1992) and recapitulate colon cancer initiation in humans by common mutation of APC Korinek et al., 1997) .
We have chosen also to use bActin-CMV!Cre-ERT2 (CreT2; Santagati et al., 2005) which drives general Cre expression but that is functional only upon addition of tamoxifen (TAM). TAM binds the modified estrogen receptor part of the Cre-ERT2 fusion protein allows translocation into the nucleus where Cre can act on loxP sites flanking the engineered floxed (fl/fl) alleles.
Loss of Apc in the small intestine of Apc fl/fl ;CreT2 mice was found to be correlated with addition of TAM by gavage for 5 days (not shown). To check the action of Cre in the intestine, we introduced a Rosa26 background in the CreT2 line and found that the entire intestinal lining of CreT2;Rosa26 mice became LacZ + (and thus blue after the X-Gal reaction) upon TAM treatment ( Fig ;CreT2 TAM-treated animals also lost weight and were euthanized following local ethical rules (not shown).
Gene expression in the intestinal epithelium and mesenchyme of Apc mutant mice
To analyze changes in gene expression in both the intestinal epithelium and surrounding mesenchyme following hyperactivation of Wnt signaling by loss of Apc, Apc fl/fl ;CreT2 and CreT2 mice treated with TAM for 5 days followed by 3 days without TAM were dissected and their small intestines treated with EDTA to separate the epithelium from the mesenchyme. The efficiency of this separation method was confirmed by the selective expression of the epithelial absorptive cell marker Villin in the epithelium, and of the mesenchymal cell marker Vimentin in the mesenchyme, as determined by qRT-PCR (Fig. 2C) .
Expression of Shh and of the Wnt pathway targets cMyc, Lgr5, Cd44 and Axin2 was enhanced 3-to 5-fold in the epithelia of Apc defloxed intestines as compared with that of controls (Fig. 2C) . In contrast, the expression of the Hh pathway genes Gli1, Ptc1 and Hip1 was enhanced $2-to 3-fold in the mesenchyme (Fig. 2C ). The expression of these genes was not enhanced in the epithelium of Apc mutant intestines and its mesenchyme also did not show enhanced expression of Wnt pathway markers (Fig. 2C) .
The data is thus consistent with an expansion of epithelial cells with a Wnt-driven crypt-like phenotype, which form adenomas, and the concomitant Hh pathway enhancement or overrepresentation of surrounding mesenchymal cells that respond to Hh signaling in mice lacking Apc, as compared with control mice.
2.4.
Systemic cyclopamine treatment enhances the survival of Apc mutant mice
To test for a possible role of Hh signaling in loss of Apc-induced lethality we first treated a cohort of mice with TAM as above and then divided it into two groups. One received intraperitoneal (IP) injections of cyclodextrin vehicle alone while the other received IP injections of cyclopaminecyclodextrin conjugates. Vehicle-injected TAM-treated mice showed an indistinguishable course to those of uninjected TAM-treated mice (not shown) and died or were sacrificed within 2-3 weeks following TAM treatment due to weight loss (Fig. 3) . In contrast, systemic inhibition of Smo by cyclopamine injection IP lead to the extension of tumorfree life and overall survival by an additional $50% (Fig. 3) . Systemic inhibition of HH signaling thus appears to have a beneficial effect counteracting loss of Apc-driven lethality.
2.5.
Conditional loss of Smo rescues the lethality of conditional loss of Apc ;CreT2 mice appeared normal and had normal survival like CreT2 mice (Fig. 4) . As before, TAM-induced Apc fl/fl ;CreT2 developed intestinal dysplasia and exhibited early lethality (Fig. 4A and B) . Importantly, however, concomitant loss of (Fig. 4A ).
Conditional loss of Smo rescues intestinal phenotypes of conditional loss of Apc
To investigate if Smo was also required for the development of specific intestinal phenotypes due to loss of Apc, serial sections of the intestines were examined. Histological analyses $3 weeks after TAM treatment revealed generalized dysplasia of TAM-treated Apc fl/fl ;CreT2 intestine with ubiquitous nuclear bcatenin labeling (Fig. 5A) , a 2.5-fold increase of BrdU incorporation (Fig. 5B) , a ±4-fold loss of Alcian blue-stained differentiated Goblet cells in crypts and villi (Fig. 5C) , and a ±3-fold increase in lysozyme-positive Paneth cells (Fig. 5D) 
Discussion
The molecular mechanisms involved in normal crypt development and tumor formation in the mouse intestine have ;CreT2 and control CreT2 mice, all treated with TAM for 5 days by gavage followed by 3 days without TAM. mRNA levels were determined by RT-qPCR and are shown, after normalization, with Gapdh as follows: Villin ·10; cMyc ·10 role of Hh signaling, and specifically of Smo, in the phenotypes driven by loss of Apc, and thus constitutive gain of Wnt signaling function, in adult mice. A number of authors have suggested that Hh signaling drives intestinal cell differentiation and that its blockade may be counterproductive as a therapeutic strategy for human colon cancer. This is based on results in the mouse intestine in which it is reported to repress Wnt signaling: Hh pathway blockade would then result in increased Wnt signaling and tumor promotion instead of inhibition (van den Brink et al., 2004; Madison et al., 2005; Kolterud et al., 2009; van Dop et al., 2009 ).
However, we have recently addressed the role of HH-GLI signaling in human colon cancers and have demonstrated that HH-GLI is essential for human CC growth, recurrence, metastasis and stem cell survival and expansion, affecting epithelial tumor cells (Varnat et al., 2009) . These discrepancies could be due to species differences (see Ruiz i Altaba, 2008) -for instance Hh signaling appears to act in a paracrine fashion in the mouse intestine (Madison et al., 2005) but in an autocrine manner in human colon cancers (Varnat et al., 2009 ) -but they could also derive from pathway utilization differences between the normal and tumorigenic contexts. We find that Shh To directly test a possible role of Hh signaling in mouse intestinal adenomas and related intestinal phenotypes due to hyperactive Wnt-bCat/Tcf signaling we have used conditional floxed alleles of Apc and Smo and a Cre driver that is active in both epithelial and mesenchymal cells. This driver was chosen to allow for inhibition of Hh signaling in both the epithelium and stroma of the resulting tumors lacking Apc.
Our results show that Smo is required for tumor formation and lethality driven by a Wnt-bCat/Tcf pathway superactivated by loss of Apc, and parallel our results in human cancers (Varnat et al., 2009 ). The lethality resulting from loss of APC in our case could be due, in principle, to effects in the intestine as well as in other sites. While we do not think the latter is the case as the lethality is due to weight loss, any other such effects are also Smo dependent. Moreover, the present results with systemic inhibition of Hh signaling with cyclopamine treatment extend our previous data showing that cyclopamine can have beneficial effects, acting to inhibit endogenous tumorigenesis in adult mice without any major side effects (Sanchez and Ruiz i Altaba, 2005) . Furthermore, the data suggests that the Hh pathway acts in parallel or downstream of Wnt-bCat/Tcf signaling in the mouse intestine.
Our data also addresses directly the role of Smo through use of conditional Smo and Apc alleles, extending and clarifying recent data using heterozygote Smo mice with an Apc hypomorphic allele (Arimura et al. 2009 ). Together, the data support a role of Smo and thus Hh signaling in the development of intestinal adenomas and related phenotypes due to hyperactivation of Wnt signaling.
If Hh signaling in mice were strictly paracrine in the intestine, tumor development would seem to require a Smo-dependent unknown signal from the mesenchyme acting back on Hh-producing epithelial cell. However, given the low levels of expression required for function, it is difficult to ignore the possibility that there could be a low level of Hh signal reception in mouse intestinal epithelial cells that is augmented in cancers, supporting autocrine signaling, or that intestinal tumors may develop de novo autocrine signaling, in both cases paralleling the role of HH-GLI signaling in human colon cancers (Varnat et al., 2009 ). Since we have not detected increased Gli1 expression in the intestinal epithelium of Apc null mice, the data support paracrine action in mice. Finally, the present results establish conditional Apc mutant adult mice as a model to test for HH antagonist function in vivo.
4.
Experimental procedures
Mouse transgenics
Apc fl/fl mice (Shibata et al., 1997) were a kind gift of P. Herrera (Soriano, 1999) were a kind gift of P. Herrera (Geneva) and were genotyped with the LacZ primers.
Tamoxifen and cyclopamine treatment
Tamoxifen (200 ll) in corn oil at 10 mg/ml (Sigma #T5648) was given to mice once daily by intragastric administration (gavage) for five consecutive days. Controls received equal amounts of corn oil only. Cyclopamine (Toronto Research or Logan) complexed with cyclodextrin or cyclodextrin alone was administered by intraperitoneal (IP) injection at 10 mg/ kg/twice daily as described (Sanchez and Ruiz i Altaba, 2005) .
Histology, X-Gal and immunostaining
Frozen sections were cut in a cryostat after OCT embedding and fixation in fresh 4% paraformaldehyde at 4°C. Tissues were prepared for paraffin sections using a standard protocol. Briefly, tissues were fixed in 4% paraformaldehyde, dehydrated in one bath of 70% ethanol (90 min), two bath of 100% ethanol (90 min each) followed by two bath of xylene (90 min each). Tissues were subsequently incubated in two serial bath of liquid paraffin (90 min each) at 60°C and finally embedded in a paraffin blocs. For staining and immunohistochemistry, 5 lm paraffin sections were hydrated with two bath of xylene (5 min each) followed by two bath of 100% ethanol (5 min each) and one bath of 70% (5 min) ethanol and finally a bath of water (5 min). Paneth cells were labeld with anti-lysozyme antibodies (DAKO). Goblet cells were revealed with Alcian Blue staining with a nuclear fast red counterstaining and H&E staining were performed using hematoxylin and a 0.5% eosin Y solution. GFP immunostaining was performed with an anti-GFP rabbit polyclonal antibody (Invitrogen).
For X-Gal staining, the digestive tracts were dissected washed with PBS and incubated with the b-galactosidase substrate overnight at room temperature (5 mM K 4 Fe(CN) 6 AE3H 2 O, 5 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 , 0.1% sodium deoxycholate, 0.02% NP40, 1 mg/ml X-Gal).
For BrdU labelling, mice were given an IP pulse of BrdU (100 ll of 20 mg/ml) 2 h before collection. Sections were labeled with a mouse anti-BrdU (U. Iowa Hybridoma bank) after acid treatment.
bcatenin immunostaining was performed using a mouse anti-bcatenin antibody (Transduction labs #C19220) after antigen retrival treatment (van de Wetering et al., 2002) . GFP immunostaining was performed with rabbit anti-GFP (Invitrogen) at 1/100 dilution.
PCR analyses
To separate the epithelium from the mesenchyme, intestines were dissected and treated with 10 mM EDTA in HBSS1X solution for 2 h. This allowed the separation of the mesenchyme from the epithelium. Following RNA extraction and cDNA preparation, quantitative RT-PCR analyses were performed with SYBR green with the following primers:
• Axin2-FOR 5 0 CTCCCCACCTTGAATGAAGA3 0 ,
• Axin2-REV 5 0 ACTGGGTCGCTTCTCTTGAA3 0 ;
• Gli1-FOR 5 0 GCTGCCTATAGCCAGTGTC3 0 ,
• Gli1-REV 5 0 GAAGCAGGTGCAAAGCCAG3 0 ;
• Gapdh-FOR 5 0 CGTCCCGTAGACAAAATGGT3 0 ,
• Gapdh-REV 5 0 GAATTTGCCGTGAGTGGAGT3 0 ;
• Lgr5-FOR 5 0 CTGCCCATCACACTGTCACT3 0 ,
• Lg5-REV 5 0 GCAGAGGCGATGTAGGAGAC3 0 ;
• Ptch1-FOR 5 0 ATGGTCCTGGCTCTGATGAC3 0 ,
• Ptch1-REV 5 0 TAGCCCTGTGGTTCTTGTCC3 0 ;
• Shh-FOR 5 0 GCAGGTTTCGACTGGGTCTA3 0 ,
• Shh-REV 5 0 GAAGGTGAGGAAGTCGCTGT3 0 ;
• Smo-FOR 5 0 CTACGGAGCCACCACCAC3 0 ,
• Smo-REV 5 0 TCCACTCGGTCATTCTCACA3 0 ;
• Vimentin-FOR 5 0 ATGCTTCTCTGGCACGTCTT3 0 ,
• Vimentin-REV 5 0 AGCCACGCTTTCATACTGCT3 0 ;
• Hip-FOR 5 0 CCACTGACCTCCGATTGCTC3 0 ,
• Hip-REV 5 0 TGCAGCAGCACTTGCCAG3 0 ;
• cMyc-FOR 5 0 TCCTGTACCTCGTCCGATTC3 0 ,
• cMyc-REV 5 0 GGTTTGCCTCTTCTCCACAG3 0 ;
• Villin-FOR 5 0 CTGTGATGTCCAGCGACTGT3 0 ,
• Villin-REV 5 0 CTGGTCTCGGATCTCTTTGG3 0 ;
• Cd44-FOR 5 0 GAATGTAACCTGCCGCTACG3 0 ,
• Cd44-REV 5 0 GGAGGTGTTGGACGTGAC3 0 ;
